Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incyte Corp
(NQ:
INCY
)
76.13
+2.01 (+2.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corp
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
The major indexes declined, but haven't fallen apart.
Via
Investor's Business Daily
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
October 30, 2024
Incyte reports strong Q3 earnings, driven by Jakafi growth, prompting BofA upgrade with a new price target of $90.
Via
Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via
Benzinga
Incyte Breaks Out To 17-Month High As Jakafi Demand Surges
October 29, 2024
Sales of the company's two key products, Jakafi and Opzelura, jumped.
Via
Investor's Business Daily
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
October 23, 2024
Via
Benzinga
This Alphabet Analyst Turns Bullish; Here Are Top 5 Downgrades For Wednesday
October 30, 2024
Via
Benzinga
Incyte to Present at Upcoming Investor Conferences
October 30, 2024
From
Incyte
Via
Business Wire
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
October 29, 2024
Incyte reports Q3 revenue of $1.04B, driven by strong Jakafi and Opzelura sales, and raises 2024 guidance amid competitive market challenges.
Via
Benzinga
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday
October 29, 2024
Via
Benzinga
Uncovering Noteworthy Technical Analysis Findings for INCYTE CORP (NASDAQ:INCY).
October 14, 2024
NASDAQ:INCY may be ready to breakout.
Via
Chartmill
A Look Into Incyte Inc's Price Over Earnings
October 10, 2024
Via
Benzinga
Assessing Incyte: Insights From 11 Financial Analysts
October 01, 2024
Via
Benzinga
Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
September 03, 2024
Via
Benzinga
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
October 29, 2024
From
Incyte
Via
Business Wire
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
October 24, 2024
From
Incyte
Via
Business Wire
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
October 10, 2024
From
Incyte
Via
Business Wire
Incyte to Report Third Quarter Financial Results
October 08, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2024
From
Incyte
Via
Business Wire
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
September 30, 2024
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC...
Via
Benzinga
Exposures
Product Safety
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
September 25, 2024
From
Incyte
Via
Business Wire
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
September 18, 2024
Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Wall Street Lower Ahead Of Interest Rate Move
September 18, 2024
Stocks are slightly lower this afternoon, as investors hope for the Federal Open Market Committee (FOMC) to issue its first interest rate cut in four years later today.
Via
Talk Markets
Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers
September 16, 2024
Intel kept running late on yet another big deal.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
September 14, 2024
From
Incyte
Via
Business Wire
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
September 14, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2024
From
Incyte
Via
Business Wire
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
August 21, 2024
From
Incyte
Via
Business Wire
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
August 16, 2024
Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in relapsed follicular lymphoma patients, showing positive progression-free...
Via
Benzinga
Exposures
Product Safety
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
August 15, 2024
From
Incyte
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.